diabetic nephropathy

The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.

The effort aims to identify a suite of markers that could aid in management of type II diabetes and related conditions like retinopathy and kidney damage.

Named PromarkerD, the test is intended to predict risk of developing kidney disease in diabetics and diagnose patients with diabetic kidney disease.

Proteomics firm Proteomics International said this week that it has received a A$1 million (US$ 1 million) grant from Commercialisation Australia – an initiative of the Australian government – to develop its protein biomarkers for diabetic nephropathy into a companion diagnostic.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – EMD Millipore and Proteomic International have signed a collaborative agreement to validate biomarkers related to diabetic nephropathy, the firms said today.

The company presented a panel of 13 biomarkers for the disease at last month's Human Proteome Organization annual meeting and is looking for partners and funding to develop it as a commercial diagnostic.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.